A B S T R A C T Type II hyperprolinemia is an inherited abnormality in amino acid metabolism characterized by elevated plasma proline concentrations, iminoglycinuria. and the urinary excretion of A1-pyrroline compounds. To define the enzymologic defect of this biochemical disorder, we developed a specific, sensitive radioisotopic assay for the proline degradative enzyme A'-pyrroline-5-carboxylic acid dehydrogenase. Using this assay, we have shown an absence of A'-pyrroline-5-carboxylic acid delhydrogenase activity in the cultured fibroblasts from three patients with type II hyperprolinemia. \Ve confirmed this result on cultured cells by demonstrating a similar absence of Al-pyrroline-5-carboxylic acid dehydrogenase activity in extracts prepared from the peripheral leukocytes of these patients. Additionally, we found significantly decreased levels of A'-pyrroline-5-carboxylic acid dehlvdrogenase activity in the leukocyte extracts from five obligate heterozygotes for type II hyperprolinemia. We also demonstrated a reduction in leukocyte AL-pyrroline-5-carboxylic acid dehydrogenase activity in three successive generations of a family.
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INTRODUCTION
The hyperprolinemias are rare metabolic disorders caused by inherited biochemical abnormalities in the pathway of proline degradation (Fig. 1 ). Both type I hyperprolinemia (HP1)1 and type II hyperprolinemia (HP2) are characterized by elevated plasma proline concentrations. The increase in renal filtered load of proline results in iminoglycinuria with increased urinary excretion of proline, hydroxyproline. and glycine (1) . The distinguishing feature of HP2, however, is the urinary excretion of large amounts of Y'-pyrroline compounds. The presence of these compounds results in a characteristic orange color when the urine of HP2 patients is reacted with o-aminobenzaldehyde (OAB) (1) .
The cause of HP1 has been shown to be a deficiency of proline oxidase, the first enzyme in the proline degradative pathwvay (2) (Fig. 1) reported an absence of A1-pyrroline-5-carboxylic acid dehydrogenase (PC dehydrogenase) in the cultured skin fibroblasts of a single individual with HP2 (3) . In the present report we extend this observation to include the fibroblasts from three patients with HP2. Furthermore, we verify the findings in cultured cells by demonstrating the absence of PC dehydrogenase in leukocyte extracts from these patients. Additionally, we show intermediate levels of enzyme activity in the leukocyte extracts of asymptomatic obligate heterozygotes and thus verify the autosomal recessive inheritance of this biochemical abnormality.
METHODS
Patient material. The pertinent data describing our four patients is presented in Table I (7) and were negative throughout the period of study. Antibiotics were not used. For biochemical studies late log-phase cells were harvested by scraping with a soft rubber policeman and collected by centrifugation. The cell pellet was washed three times with phosphate-buffered saline and sonicated with the micro tip of a Branson model W180 sonicator (Branson Sonic Power, Co., Danbury, Conn.) at a setting of 2-3 for 40 s in 1 ml buffer appropriate for the enzyme assay. The enzyme activity of these extracts was usually assayed on the day of preparation although activity was stable for at least 4 wk at -20°C.
Leukocyte extract preparation. Purified leukocytes were prepared from 10 ml fresh heparinized (10 U/ml) blood by dextran sedimentation and osmotic lysis of erythrocytes (8) . The leukocytes were washed three times with phosphate-buffered saline and sonicated for 40 s in 1 ml of 50 mM Tris buffer pH 8.2.
Enzyme assays. We devised a specific radioisotopic assay for PC dehydrogenase similar to our previously reported assay for PC reductase (9) . The standard reaction mixture, as modified from that of Strecker (10) Boston , Mass.) using partially purified ornithine-5-amino transferase according to our previously published method (11) . After incubation at 30°C for 30 min in a Dubnoff shaker, the reaction was stopped by the addition of 0.05 ml 6 N HCl. 0.2 ml of this acidified reaction mixture was then mixed with an equal volume of a solution of OAB (10 mg/ml in 1 N HCI and 10% ethanol). The OAB quantitatively combines with unreacted PC forming a dihydroquinazolinium compound which remains at the top of a Dowex-50W column (150 X 5 mm) while the reaction product, [U-14C]glutamate, is eluted with 1 N HCI (9).
The glutamate elutes as a peak between 7 and 12 ml eluent. A 3-ml aliquot of this 5-ml fraction is mixed with 12 ml PC reductase, ornithine-a-aminotransferase, and proline oxidase were assayed as previously described (9, 11, 12) . Protein was determined by the method of Lowry et al. (13) . DNA was determined by the method of Burton (14) .
RESULTS
Fibroblast PC dehydrogenase activity. PC dehydrogenase was readily detectable in extracts of normal htuman fibroblasts. This activity was stable for 1 mo at -20°C and was not affected by freezing and thawing.
At standard reaction conditions of pH 8.2 and 300C, enzyme-dependent production of product ["4C]glutamate increased linearly with increasing amounts of added fibroblast protein from 5 to 70 mg (Fig. 2) . Also with standard amounts of fibroblast protein, product formation increases linearly for up to 30 min (Fig. 2) . The sensitivity of this method allows several assays to be performed on an extract of as few as 107 fibroblasts.
PC dehyd)rogeiiase in. HP9 fibroblasts. PC dehydrogenase activity was completely absent in extracts of HP2 fibroblasts with an assay able to detect as little as 0.2 nmol product (Fig. 3) . Addition of as much as 180 ,ug HP2 fibroblast protein to a standard assay mixture did not increase the ["4C]glutamate radioactivity recovered above either NAD+ or enzyme blanks. Comparable amouints of control fibroblast protein produced a greater than 25-fold over blank increase in recovered radioactivitv. Furthermore, 100-fold irncreases in PC concentrationi to levels well above the Km or substitution of NADP+ for NAD+ as cofactor also were ineffective in increasing HP? fibroblast PC dehydrogenase activity above blank.
The possibility of an inhibitor causing the absence of PC dehydrogenase activity in HP2 cells was eliminated bv an experimileint in wlhich the addition of 93 Ag HP2 protein to an assay mixtuire containing 16 ,ug normal fibroblast protein did not alter the activity of the normal PC dehNdrogenase enzyme (3) .
We also considered the possibility that the apparent lack of activity in HP2 extracts resulted from the con- Specificity of tile enzymne defect in HP2 fibroblasts.
To ensure that the absence of PC dehydrogenase was a specific defect in HP2 fibroblasts, we compared the activity of two proline biosynthetic enzyines, ornithine-8-aminotransferase and PC reductase, in HP2 and control fibroblasts (Table II) . Activities of these two enzymes did not differ significantly in HP2 and control cells. We also assayed control and HP2 extracts for proline oxidase, the enzyme deficient in HP1. Unfortunately, we were unable to detect proline oxidase activity in control cells despite the use of an assay capable of detecting as little as 100 pmol of product (12) . Additional attempts at measuring proline oxidase using concentrated mitochondrial preparations from control cells yielded similar negative results.
Leukocyte PC dehydrogenase. To verify and extend our findings in cultured fibroblasts, we assayed PC dehydrogenase activity in extracts of fresh peripheral leukocytes obtained from individuals with HP2 and members of their families (Fig. 4) mal (4) (5) (6) . all five obligate heterozygotes for HP2 and one of two maternal grandparents in the E. D. family had leukocyte PC dehydrogenase activity at least 2 SD below the normal leukocyte mean (Fig. 5) . These results prove the autosomal recessive inheritance of HP2. DISCUSSION HP2 is a rare, inherited, metabolic disorder of proline degradation. The biochemical abnormalities of this condition include elevated plasma proline concentrations, iminoglycinuria, and the urinary excretion of OABreactive material. Our results clearly show an absence of PC dehydrogenase activity in the cultured skin fibroblasts and fresh peripheral leukocytes of HP2 patients. The metabolic block resulting from this enzymatic defect explains the biochemical abnormalities described in HP2. PC derived from either proline or ornithine accumulates because of the block in conversion of PC to glutamate (Fig. 1) . A portion of the accumulated PC is excreted in the urine and results in the positive urine OAB reaction diagnostic of HP2. The bulk of the accumulated PC, however, is converted to proline by PC reductase resulting in markedly elevated plasma proline concentrations.
The inheritance of HP2 is clearly autosomal recessive. The leukocyte PC dehydrogenase activity of the heterozygotes is approximately 40% that of normals and thus allows heterozygote determination. This level of activity is apparently sufficient under usual conditions to maintain the plasma proline concentrations in the normal range. When stressed with a proline load, however, the heterozygotes, as shown by Simila (15) , do demonstrate decreased proline tolerance in comparison with controls.
The ratio of the intracellular concentrations of PC and proline in patients with HP2 probably reflects the activities of PC reductase and proline oxidase. PC reductase in liver and kidney has a two to three times higher maximal velocity and a 10-fold lower Km for PC (0.2 mM) than proline oxidase has for proline (2 mM), thus favoring the accumulation of proline' (16) . Fur- thermore, PC reductase in liver and kidney is relatively insensitive to inhibition by proline (16) (17) (18) tribution from ornithine to the proline pool in HP2. Normally, a significant amount of ornithine may be converted to PC by ornithine-8-aminotransferase and thence to glutamate by PC dehydrogenase (19) . This pathway is not interrupted in HP1. In HP2, however, with a block in the conversion of PC to glutamate, PC derived from ornithine will accumulate and, in turn, add to the proline pool. In support of the significance of this contribution by ornithine to PC, Simila and co-workers (20) have shown a 10 to 20-fold increase in urine OABreactive material after an ornithine load in patients with HP2. Thus, in HP2, the proline pool derives not only from undegraded proline but also from ornithine, and therefore it is reasonable to expect that proline concentrations will be higher in HP2 than in HP1.
The urinary excretion of OAB-reactive material is characteristic of HP2. This OAB-reactive material was initially thought to be PC, but recent evidence shows that the majority of the OAB-reactive material is A'-pyrroline-3-hydroxy-5-carboxylic acid (30HPC), the oxidized degradative product of hydroxyproline (5, 6) . This observation suggests an abnormality of hydroxyproline degradation in HP2. Furthermore, on the basis of co-purification of the dehydrogenase activities for PC and 30HPC, Adams and Goldstein have previously suggested (21) that a single enzyme catalyzes the oxidation of both PC and 30HPC. We have taken advantage of HP2 as a naturally occurring mutant and have recently obtained evidence proving a complete block in oxidation of 30HPC to y-hydroxyglutamate in HP2 (22) . This result provides strong genetic evidence for a single dehydrogenase catalyzing the oxidation of both PC and 30HPC.
Although significant amounts of PC and 30HPC are excreted by patients with HP2, these substances are undetectable in their plasma (6) . Thus, the source of the urinary PC and 30HPC may be from renal metabolism of proline and hydroxyproline. Holtzapple and coworkers (23) have shown in human kidney cortex slices that 90% of proline transported by the tubule cells is rapidly metabolized to glutamate. Presumably, intracellular metabolism is equally important for hydroxyproline transported by the kidney. In HP2 the kidney tubule cells are exposed to saturating concentrations of proline and hydroxyproline. In HP2, however, the degradation of these amino acids is blocked. Thus, the tubule cells must accumulate large amounts of 30HPC and PC which could diffuse back into the tubule lumen and appear in the urine.
The clinical implications of HP2 are still unclear (1, 24) . Possible bias resulting from the method of patient ascertainment prevents a clear delineation of the clinical phenotype. Two of our four patients (E. D. and M. B.) were diagnosed during evaluation for transient behavior problems. Another (G. F.) was diagnosed dur-ing a work-up for focal seizures associated with fever. Our fourth patient (K. K.) was ascertained by the mass newborn screening program in Massachusetts. Despite moderate dietary protein restriction, her plasma proline concentrations have remained markedly elevated. At age 3 yr, she has normal developmental milestones and has not had seizures. All of our patients have had normal physical growth and have I.Q.'s in the normal to low-normal range (4-6). Thus, HP2 certainly is not a cause of severe illness. Long-term prospective study of patients found by mass screening will be necessary to delineate completely the clinical significance of HP2.
